Budesonide controlled-release - Cosmo Pharmaceuticals

Drug Profile

Budesonide controlled-release - Cosmo Pharmaceuticals

Alternative Names: Budesonide controlled release; Budesonide CR; Budesonide MMX®; budesonide multimatrix; Cortiment; Cortiment MMX; FE 999315; Uceris oral

Latest Information Update: 30 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Developer Cosmo Pharmaceuticals; Ferring Pharmaceuticals; Salix Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ulcerative colitis

Most Recent Events

  • 24 Apr 2018 Cosmos Pharmaceuticals enters into a settlement agreement with Argentum Pharmaceuticals related to IPR petition challenging an Orange book listed patent for budesonide in USA
  • 12 Apr 2018 Arbitral Tribunal rules in favour of Valeant Pharmaceuticals in budesonide controlled-release (UCERIS®) arbitration
  • 02 Mar 2018 Phase-III clinical trials in Ulcerative colitis (In adults, In adolescents, In the elderly) in Japan (PO) (NCT03412682)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top